Statin Tedavisinin Kılavuza Uygunluğunun ve Hasta Uyuncunun Değerlendirilmesi

Abstract

Kızıldağ, B., Evaluation of Compliance with Guidelines and Patient Adherence of Statin Therapy, Hacettepe University Graduate School of Health Sciences, Master Thesis in Clinical Pharmacy, Ankara, 2023. Atherosclerotic cardiovascular disease (ASCVD) is the most important cause of mortality and morbidity in developed and developing countries. Dyslipidemia is one of the most important risk factors that increase the risk of developing ASCVD. Statins have been shown to reduce cardiovascular events. The aim of this study is to evaluate the necessity and appropriateness of statin therapy according to the 2021 European Society of Cardiology/European Atherosclerosis Society Guidelines on cardiovascular diseases prevention in clinical practice by the clinical pharmacist of the patients hospitalized in the internal medicine service, and to determine the reasons for non-compliance by evaluating the compliance with the treatment. This thesis study was carried out between September 2022 and March 2023 in the inpatient internal medicine services of a university hospital. Total of 370 patients over 40 years of age (51.1% female, mean age±standard deviation 64.67±12.7 years) were included in the study. 38.8% of all recommendations to physicians regarding statin therapy were accepted. While compliance with the guideline was 40.3% at the beginning, with the contribution of the clinical pharmacist, compliance with the guideline increased to 54.1% at discharge (p<0.001). In addition, while 29.2% of patients whose low-density lipoprotein level were not within the target range were in compliance with the orders beforehand, compliance with the rules at discharge increased to 46.2% (p<0.001). In the evaluation made by calling the patients by phone 3 months after discharge, it was found that the patients were compatible with statin therapy and the most common reason for discontinuing the treatment was the recommendation of the physician. It is important to raise awareness about the risk profile of physicians in the management of dyslipidemia in line with current guidelines and to include the clinical pharmacist in a multidisciplinary team for optimal treatment management in these patients.